SCHEMBL83967

SCHEMBL83967

COc1ncc(C(C)C)cc1N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.50
CASP1 P29466 1/20 0.50
AURKA O14965 1/20 0.49
TTK P33981 1/20 0.49
AURKB Q96GD4 1/20 0.49
INCENP Q9NQS7 1/20 0.49
PIK3CA P42336 6/20 0.44
GAA P10253 2/20 0.37
ALDH1A1 P00352 2/20 0.37
ALOX12 P18054 1/20 0.37
HTT P42858 1/20 0.37
HIF1A Q16665 1/20 0.37
P2RX3 P56373 3/20 0.33
P2RX2 Q9UBL9 3/20 0.33
POLB P06746 1/20 0.33
GFER P55789 1/20 0.33
MTOR P42345 1/20 0.32
PIK3R1 P27986 2/20 0.32
DHFR P00374 1/20 0.32
NPC1 O15118 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24139835 0.85 MAPT (0.51) MAPTCASP1AURKATTKAURKB
SCHEMBL14060339 0.83 MAPT (0.49) MAPTCASP1AURKATTKAURKB
SCHEMBL24139898 0.83 ALDH1A1 (0.36) MAPTCASP1AURKATTKAURKB
SCHEMBL12736481 0.78 RECQL (0.33) MAPTCASP1AURKATTKAURKB
SCHEMBL799306 0.78 PIK3CA (0.38) PIK3CAALDH1A1P2RX3P2RX2MTOR
SCHEMBL16133709 0.78 GABRA1 (0.35) MAPTCASP1AURKATTKAURKB
SCHEMBL10141659 0.77 GABRA1 (0.38) MAPTCASP1AURKATTKAURKB
SCHEMBL12089821 0.77 SMN1; SMN2 (0.39) MAPTCASP1PIK3CAALDH1A1P2RX3
SCHEMBL10141619 0.77 PIK3CA (0.42) MAPTPIK3CAP2RX3P2RX2MTOR
SCHEMBL16248217 0.77 CRHR1 (0.35) MAPTCASP1ALDH1A1P2RX3P2RX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2710018-B1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS FUNDACION CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) 2021-12-29 EP disclosed
US-9878987-B2 HSP70 modulators and methods for making and using the same MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2018-01-30 US disclosed
US-20170233352-A1 HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME MEMORIAL SLOAN KETTERING CANCER CENTER 2017-08-17 US disclosed
US-8865732-B2 Heterocyclic compounds and uses thereof NOVARTIS AG (CH) 2014-10-21 US disclosed
US-20130210818-A1 Novel Heterocyclic Compounds and Uses Thereof NOVARTIS AG (CH) 2013-08-15 US disclosed
WO-2012156756-A2 NEW COMPOUNDS CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) 2012-11-22 WO disclosed
US-8129394-B2 Heteroaryl-substituted imidazole compounds and uses thereof NOVARTIS AG (CH) 2012-03-06 US disclosed
US-20100003246-A1 Novel heterocyclic compounds and uses therof NOVARTIS AG (CH) 2010-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233352-A1 HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME HSPA2, HSP90AA1, HSP90AB1 MAPT 765/4885CASP1 1939/4885AURKA 2176/4885
US-20100003246-A1 Novel heterocyclic compounds and uses therof BRAF, ARAF, KRAS MAPT 3320/4885CASP1 2099/4885AURKA 145/4885
US-20130210818-A1 Novel Heterocyclic Compounds and Uses Thereof BRAF, RAF1, HRAS MAPT 4170/4885CASP1 2765/4885AURKA 514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.